ABSI logo

ABSCI CORP

ABSINASDAQ
🏆 #2158 by market capEarnings Nov 10US Equity
$754.59▼ $40.97 (−5.43%)
Simulated price
🔔
Track ABSI
Get earnings, price moves & breaking news on Telegram
Track
24h▼ 5.4%
7d—
14d—
30d—
ytd—
1y—
🏦Market Cap
$1.61B
Small Cap
📈Revenue Growth (YoY)
-38.2%
Declining
📊Gross Margin
-255.9%
Thin
💵FCF Margin
-6981.0%
Thin
⚖️P/S Ratio
1029.9x
Expensive
Otter Score
56
Weak
No chart data available for ABSI.

Trading Snapshot

Day Range
$751.61 – $763.27
52-Week Range
$2.24 – $12.06
Volume
$6.84B
Avg Volume
$8.85B
Shares Outstanding
169.4M
Next Earnings
Nov 8, 2026

Fundamentals Snapshot

Annual Revenue
$3M
Last Q Revenue
$318,000
P/E Ratio
-11.9
P/S Ratio
1029.9x
EPS (TTM)
$-0.77
Dividend Yield
0.00%
Dilution (1yr)
+31.0%

Why Investors Own ABSI

  • ✓High-growth profile — revenue up +4.8% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 27% gross margin and 17% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

ABSI logo

ABSCI CORP

ABSI
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$3M▼ −38.2% YoY
Gross MarginOf every $1 of sales, how much is left after the direct cost of making the product/service. Higher = more efficient.
-319.4%▼ −75.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$125M▲ +14.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$94M▲ +29.2% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
150.6M▲ +31.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$15M▼ −$16M YoY
StockOtter · stockotter.space

About ABSCI CORP

Absci Corporation operates as a biopharmaceutical company primarily focused on discovering novel drug targets and developing new therapeutic compounds. Leveraging its distinctive integrated drug creation platform, the firm generates potential biologic medicines and essential cell lines for manufacturing, which it provides to its collaborators, predominantly within the United States. This advanced platform is instrumental in facilitating the development of biologics by meticulously integrating the traditionally separate stages of drug discovery and cell line engineering into one streamlined process. Absci Corporation was founded in 2011 and is based in Vancouver, Washington.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Weak
56/100

Analyst Price Target

ⓘ
Average Target
$875.33
▲ +16.0% Upside
High Target$1,090.63
Low Target$680.71
Based on 10 analysts

Latest News & Updates

🚀
CNBC·2h ago

ABSCI CORP tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
CNBC·5h ago

Analysts lift ABSI price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

ABSCI CORP announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.